Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 13.4%

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 2,970,886 shares, a decline of 13.4% from the February 12th total of 3,431,739 shares. Currently, 12.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 580,096 shares, the short-interest ratio is presently 5.1 days. Based on an average daily trading volume, of 580,096 shares, the short-interest ratio is presently 5.1 days. Currently, 12.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors have recently modified their holdings of the company. Allworth Financial LP acquired a new position in shares of Immix Biopharma in the fourth quarter valued at approximately $30,000. Mathes Company Inc. purchased a new position in Immix Biopharma in the fourth quarter valued at $56,000. Balyasny Asset Management L.P. acquired a new stake in Immix Biopharma in the 4th quarter valued at about $67,000. Kera Capital Partners Inc. purchased a new position in shares of Immix Biopharma in the 4th quarter valued at about $68,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth about $112,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Citizens Jmp assumed coverage on shares of Immix Biopharma in a research note on Monday, March 9th. They set an “outperform” rating and a $23.00 target price on the stock. Mizuho began coverage on shares of Immix Biopharma in a report on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX traded up $0.71 during midday trading on Tuesday, reaching $11.48. 693,587 shares of the stock were exchanged, compared to its average volume of 856,053. The stock has a market capitalization of $607.98 million, a P/E ratio of -14.91 and a beta of 0.25. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $11.61. The company has a 50 day simple moving average of $6.99 and a 200 day simple moving average of $4.84.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.